Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators

Cell & Bioscience

Bin Zhao¹  Xiaocan Guo¹ 

[1] Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China

关键词: Wnt pathway;    GPCR signaling;    mechanical stress;    The Hippo pathway;    TAZ;    YAP;   

Others  :  791562
DOI  :  10.1186/2045-3701-3-33

 received in 2013-06-14, accepted in 2013-06-30,  发布年份 2013

【 摘 要 】

YAP and TAZ are transcription coactivators and effectors of the Hippo pathway, which play a key role in organ size control. Through interaction with transcription factors such as TEADs, they activate gene transcription and thus promote cell proliferation, inhibit apoptosis, and regulate cell differentiation. Dysregulation of YAP/TAZ was found to correlate with human cancers. The oncogenic roles of these proteins were also demonstrated in animal models. The growth promoting activity of YAP/TAZ is limited by the Hippo tumor suppressor pathway through phosphorylation-induced cytoplasmic retention and destabilization. Recently, it was found that YAP and TAZ mediate responses to several extracellular signals including mechanical stress, GPCR signaling, and the Wnt signaling pathway. All these growth-regulating signals play important roles in normal development and cancer. In this review, we would like to discuss the function of YAP and TAZ as effectors of these physiological signals.

【 授权许可】

   
2013 Guo and Zhao; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Zhao B, Li L, Lei Q, Guan KL: The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010, 24(9):862-874.
• [2]Yu F-X, Guan K-L: The Hippo pathway: regulators and regulations. Genes Dev 2013, 27(4):355-371.
• [3]Xu T, Wang W, Zhang S, Stewart RA, Yu W: Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 1995, 121(4):1053-1063.
• [4]Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ: The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 1995, 9(5):534-546.
• [5]Kango-Singh M, Nolo R, Tao C, Verstreken P, Hiesinger PR, Bellen HJ, Halder G: Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development 2002, 129(24):5719-5730.
• [6]Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA, Hariharan IK: Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002, 110(4):467-478.
• [7]Harvey KF, Pfleger CM, Hariharan IK: The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 2003, 114(4):457-467.
• [8]Wu S, Huang J, Dong J, Pan D: Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003, 114(4):445-456.
• [9]Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G: Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 2003, 5(10):914-920.
• [10]Pantalacci S, Tapon N, Leopold P: The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 2003, 5(10):921-927.
• [11]Jia J, Zhang W, Wang B, Trinko R, Jiang J: The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev 2003, 17(20):2514-2519.
• [12]Lai ZC, Wei X, Shimizu T, Ramos E, Rohrbaugh M, Nikolaidis N, Ho LL, Li Y: Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 2005, 120(5):675-685.
• [13]Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al.: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007, 21(21):2747-2761.
• [14]Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D: Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130(6):1120-1133.
• [15]Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL: TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008, 28(7):2426-2436.
• [16]Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL: TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009, 284(20):13355-13362.
• [17]Zhao B, Ye X, Yu J, Li L, Li W, Li S, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, et al.: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008, 22(14):1962-1971.
• [18]Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A, Pan D: The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 2010, 24(21):2383-2388.
• [19]Barry ER, Morikawa T, Butler BL, Shrestha K, de La Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S: Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2012, 493(7430):106-110.
• [20]Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al.: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125(7):1253-1267.
• [21]Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA: Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008, 39(11):1582-1589.
• [22]Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W: A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008, 68(8):2592-2598.
• [23]Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al.: The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147(4):759-772.
• [24]Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G: Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013, 15(6):637-646.
• [25]Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al.: Role of YAP/TAZ in mechanotransduction. Nature 2011, 474(7350):179-183.
• [26]Miller E, Yang J, DeRan M, Wu C, Su AI, Bonamy G, Liu J, Peters EC, Wu X: Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem Biol 2012, 19(8):955-962.
• [27]Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al.: Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150(4):780-791.
• [28]Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S: Role of TAZ as mediator of Wnt signaling. Cell 2012, 151(7):1443-1456.
• [29]Sudol M: Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994, 9(8):2145-2152.
• [30]Komuro A, Nagai M, Navin NE, Sudol M: WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003, 278(35):33334-33341.
• [31]Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y: A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999, 18(9):2551-2562.
• [32]Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML: TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001, 15(10):1229-1241.
• [33]Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR, et al.: Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011, 144(5):782-795.
• [34]Fossdal R, Jonasson F, Kristjansdottir GT, Kong A, Stefansson H, Gosh S, Gulcher JR, Stefansson K: A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Hum Mol Genet 2004, 13(9):975-981.
• [35]Kitagawa M: A Sveinsson's chorioretinal atrophy-associated missense mutation in mouse Tead1 affects its interaction with the co-factors YAP and TAZ. Biochem Biophys Res Commun 2007, 361(4):1022-1026.
• [36]Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ, et al.: Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009, 139(4):757-769.
• [37]Oh H, Slattery M, Ma L, Crofts A, White KP, Mann RS, Irvine KD: Genome-wide association of Yorkie with chromatin and chromatin-remodeling complexes. Cell Rep 2013, 3(2):309-318.
• [38]Koontz LM, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, Huang B, Chen Q, Wu S, Pan D: The hippo effector yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev Cell 2013, 25(4):388-401.
• [39]Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR: YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007, 17(23):2054-2060.
• [40]Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S: Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 2010, 70(21):8517-8525.
• [41]Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006, 103(33):12405-12410.
• [42]Cao X, Pfaff SL, Gage FH: YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev 2008, 22(23):3320-3334.
• [43]Zhang H, Pasolli HA, Fuchs E: Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A 2011, 108(6):2270-2275.
• [44]Silvis MR, Kreger BT, Lien WH, Klezovitch O, Rudakova GM, Camargo FD, Lantz DM, Seykora JT, Vasioukhin V: α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1. Sci Signal 2011, 4(174):ra33.
• [45]Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, et al.: The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 2010, 24(11):1106-1118.
• [46]Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, et al.: TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000, 19(24):6778-6791.
• [47]Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW, Wrana JL: TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008, 10(7):837-848.
• [48]Murakami M, Tominaga J, Makita R, Uchijima Y, Kurihara Y, Nakagawa O, Asano T, Kurihara H: Transcriptional activity of Pax3 is co-activated by TAZ. Biochem Biophys Res Commun 2006, 339(2):533-539.
• [49]Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, Magnuson TR, O'Neal W, Milgram SL: Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol 2006, 26(1):77-87.
• [50]Makita R, Uchijima Y, Nishiyama K, Amano T, Chen Q, Takeuchi T, Mitani A, Nagase T, Yatomi Y, Aburatani H, et al.: Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 2008, 294(3):F542-F553.
• [51]Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, Qi Z, Ponniah S, Hong W, Hunziker W: Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci U S A 2007, 104(5):1631-1636.
• [52]Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, et al.: TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309(5737):1074-1078.
• [53]Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, Geng J, Tian J, Sun X, Qin F, et al.: The Ets Transcription Factor GABP Is a Component of the Hippo Pathway Essential for Growth and Antioxidant Defense. Cell Rep 2013, 3(5):1663-1677.
• [54]Huang J, Wu S, Barrera J, Matthews K, Pan D: The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005, 122(3):421-434.
• [55]Hao Y, Chun A, Cheung K, Rashidi B, Yang X: Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008, 283(9):5496-5509.
• [56]Oka T, Mazack V, Sudol M: Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 2008, 283(41):27534-27546.
• [57]Zhao B, Li L, Tumaneng K, Wang CY, Guan KL: A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010, 24(1):72-85.
• [58]Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, et al.: Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A 2011, 108(49):E1312-E1320.
• [59]Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D: The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010, 19(1):27-38.
• [60]Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, Li T, Chan SW, Lim CJ, Hong W, et al.: The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem 2010, 285(48):37159-37169.
• [61]Chan SW, Lim CJ, Chong YF, Venkatesan Pobbati A, Huang C, Hong W: Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011, 286(9):7018-7026.
• [62]Wang W, Huang J, Chen J: Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem 2011, 286(6):4364-4370.
• [63]Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL: Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011, 25(1):51-63.
• [64]Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D, Bader GD, Sidhu SS, Vandekerckhove J, Gettemans J, et al.: Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J 2010, 432(3):461-472.
• [65]Remue E, Meerschaert K, Oka T, Boucherie C, Vandekerckhove J, Sudol M, Gettemans J: TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner. FEBS Lett 2010, 584(19):4175-4180.
• [66]Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M, et al.: The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS One 2013, 8(4):e61916.
• [67]Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH, Zhang J: PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 2013, 32(10):1266-1273.
• [68]Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI, Wang Q: YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 2013, 32(17):2220-2229.
• [69]Wang W, Huang J, Wang X, Yuan J, Li X, Feng L, Park JI, Chen J: PTPN14 is required for the density-dependent control of YAP1. Genes Dev 2012, 26(17):1959-1971.
• [70]Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, Rossant J, Wrana JL: The crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev Cell 2010, 19(6):831-844.
• [71]Nishioka N, Inoue K, Adachi K, Kiyonari H, Ota M, Ralston A, Yabuta N, Hirahara S, Stephenson RO, Ogonuki N, et al.: The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev Cell 2009, 16(3):398-410.
• [72]Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al.: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139(5):891-906.
• [73]Engler AJ, Sen S, Sweeney HL, Discher DE: Matrix elasticity directs stem cell lineage specification. Cell 2006, 126(4):677-689.
• [74]Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL: Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012, 26(1):54-68.
• [75]Wada K, Itoga K, Okano T, Yonemura S, Sasaki H: Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138(18):3907-3914.
• [76]Sansores-Garcia L, Bossuyt W, Wada K, Yonemura S, Tao C, Sasaki H, Halder G: Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J 2011, 30(12):2325-2335.
• [77]Mo J-S, Yu F-X, Gong R, Brown JH, Guan K-L: Regulation of the Hippo–YAP pathway by protease-activated receptors (PARs). Genes Dev 2012, 26(19):2138-2143.
• [78]Lappano R, Maggiolini M: G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011, 10(1):47-60.
• [79]Hernandez NA, Correa E, Avila EP, Vela TA, Perez VM: PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study. J Transl Med 2009, 7:47. BioMed Central Full Text
• [80]Paschke R, Ludgate M: The thyrotropin receptor in thyroid diseases. N Engl J Med 1997, 337(23):1675-1681.
• [81]Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, et al.: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 2011, 43(11):1119-1126.
• [82]Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC: Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457(7229):599-602.
• [83]Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al.: Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363(23):2191-2199.
• [84]Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, et al.: Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009, 15(6):539-550.
• [85]Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006, 5(12):997-1014.
• [86]Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y, Xiong Y, Lei QY, Guan KL: The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFbeta-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem 2012, 287(31):26245-26253.
• [87]Konsavage WM, Yochum GS: Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways. Acta Biochim Biophys Sin 2013, 45(2):71-79.
• [88]Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC: β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis. Cell 2013, 153(1):267-270.
• [89]Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF: Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011, 332(6028):458-461.
• [90]Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E: A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling. EMBO J 2012, 31(5):1109-1122.
• [91]Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, et al.: The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 2010, 18(4):579-591.
• [92]Li VS, Clevers H: Intestinal Regeneration: YAP—Tumor Suppressor and Oncoprotein? Curr Biol 2013, 23(3):R110-R112.